Results 101 to 110 of about 405 (144)

Cefepime-Taniborbactam in Complicated Urinary Tract Infection [PDF]

Aleksandrovs Andrejs, Bajory Zoltán, Dane Aaron, Dorr MaryBeth, et al., Gasink Leanne B., Henkel Tim, Kollaborációs szervezet: CERTAIN-1 Study Team, Lietuvietis Vilnis, McGovern Paul C., McLeroth Patrick, Moeck Greg, Petersons Aivars, Tarek Ali, Tenke Péter, Wagenlehner Florian M.   +15 more
core   +1 more source

Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review. [PDF]

JAC Antimicrob Resist
Alarcia-Lacalle A, Canut-Blasco A, Solinís MÁ, Isla A, Rodríguez-Gascón A.   +4 more
europepmc   +1 more source

Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [PDF]

Antimicrob Agents Chemother
Le Terrier C, Mlynarcik P, Sadek M, Nordmann P, Poirel L.   +4 more
europepmc   +1 more source

Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024. [PDF]

Pharmaceuticals (Basel)
Wang Z, Sun X, Sun M, Wang C, Yang L.
europepmc   +1 more source

The Pharmaceutical Industry in 2024: An Analysis of the FDA Drug Approvals from the Perspective of Molecules. [PDF]

Molecules
de la Torre BG, Albericio F.
europepmc   +1 more source

Comparison of in vitro activity of cefepime-enmetazobactam and other carbapenem-sparing agents for gram-negative uropathogens

IP International Journal of Medical Microbiology and Tropical Diseases
Kalaivani Ramakrishnan, Arunava Kali, Sarah Korah, Thouheedha Banu S, Srirangaraj Sreenivasan   +4 more
openaire   +1 more source

Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review. [PDF]

Crit Care
Horstink MMB, Rietdijk WJR, Geel DR, Deetman PE, Endeman H, Koch BCP, den Uil CA.   +6 more
europepmc   +1 more source

Challenges of Carbapenem-Resistant <i>Enterobacteriaceae</i> in the Development of New β-Lactamase Inhibitors and Antibiotics. [PDF]

Antibiotics (Basel)
Leroux P, Bornet C, Bolla JM, Cohen A.
europepmc   +1 more source

New Agents Are Coming, and So Is the Resistance. [PDF]

Antibiotics (Basel)
Keck JM, Viteri A, Schultz J, Fong R, Whitman C, Poush M, Martin M.   +6 more
europepmc   +1 more source

Monte-Carlo simulations to assess the probability of target attainment for cefepime and enmetazobactam in patients with complicated urinary tract infections

Monte-Carlo simulations to assess the probability of target attainment for cefepime and enmetazobactam in patients with complicated urinary tract infections
Jannik Vollmer, Juan Quevedo, Nathalie Dunkel, Anne Santerre Henriksen, Matthias Machacek   +4 more
openaire   +1 more source